297,894 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Alberta Investment Management Corp

Alberta Investment Management Corp bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 297,894 shares of the medical equipment provider's stock, valued at approximately $25,646,000. Alberta Investment Management Corp owned 0.15% of Zimmer Biomet at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Main Management ETF Advisors LLC boosted its holdings in Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider's stock valued at $986,000 after acquiring an additional 112 shares during the last quarter. Citizens National Bank Trust Department increased its position in shares of Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider's stock worth $85,000 after buying an additional 141 shares during the period. Oppenheimer & Co. Inc. increased its position in shares of Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider's stock worth $1,831,000 after buying an additional 152 shares during the period. TD Private Client Wealth LLC raised its stake in Zimmer Biomet by 15.3% during the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider's stock worth $104,000 after buying an additional 153 shares during the last quarter. Finally, Leonteq Securities AG raised its stake in Zimmer Biomet by 5.3% during the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider's stock worth $277,000 after buying an additional 153 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZBH. Barclays cut their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating on the stock in a research report on Wednesday, April 29th. Sanford C. Bernstein lifted their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. Wells Fargo & Company dropped their price objective on Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 29th. Truist Financial upped their target price on Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. decreased their target price on Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating for the company in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $104.42.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.28% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $100.52 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The business's fifty day moving average is $91.51 and its 200 day moving average is $90.56. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The stock has a market cap of $19.17 billion, a P/E ratio of 24.46, a P/E/G ratio of 3.20 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. Zimmer Biomet's revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source